A US approval of Novavax's (NVAX) COVID-19 vaccine is in limbo after the Food and Drug Administration missed a deadline for a full approval of the treatment, The Wall Street Journal reported Wednesday.
The FDA previously allowed emergency use of Novavax's vaccine and the agency's decision would have determined whether to grant the vaccine a normal, full approval, the report said, citing people familiar with the matter.
Novavax's application is still reportedly pending and could be approved by the agency at any time, the sources said.
Novavax and the FDA did not immediately respond to requests for comment from MT Newswires.
NVAX shares were up 3% in recent trading.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Price: 6.18, Change: +0.18, Percent Change: +3.02
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。